Irritable Bowel Syndrome (IBS) is considered to be the most common gastrointestinal disorder. Current treatments for IBS have limited efficacy and severe side effects have been reported in recently approved drugs. The Spanish biotech company AB-BIOTICS has developed I3.1, the first probiotic formula which produces a global improvement of quality of life in IBS patients. AB-BIOTICS is looking for pharmaceutical companies interested in licensing I3.1 worldwide.
Link to this comment:
All Comments (0)